Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.54 |
| ▸ | DRD3 | P35462 | 10/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD5 | P21918 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12363792 | 0.86 | DRD2 (0.66) | DRD2DRD3HRH3MAPK1DRD1 | |
| SCHEMBL741631 | 0.85 | DRD2 (0.54) | DRD2DRD3HRH3MAPK1DRD1 | |
| SCHEMBL742988 | 0.84 | — | — | |
| SCHEMBL22788530 | 0.77 | DRD2 (0.44) | DRD2DRD3HRH3 | |
| SCHEMBL1427663 | 0.77 | DRD2 (0.58) | DRD2DRD3HRH3MAPK1GRM5 | |
| SCHEMBL14970397 | 0.74 | MAPK1 (0.51) | DRD2DRD3MAPK1GRM5 | |
| SCHEMBL740255 | 0.74 | DRD2 (0.42) | DRD2DRD3MAPK1 | |
| Propionic Acid SCHEMBL29011051 | 0.73 | MAPK1 (0.50) | DRD2DRD3MAPK1CYP2C19GRM5 | |
| SCHEMBL30861099 | 0.72 | MAPK1 (0.52) | DRD2DRD3MAPK1GRM5 | |
| SCHEMBL9871027 | 0.71 | DRD2 (0.61) | DRD2DRD3MAPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | US | disclosed |
| CN-108570059-B | Compound with PRMT5 inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2022-02-08 | — | — | CN | disclosed |
| US-10934309-B2 | Tricyclic quinone derivative | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3772513-A1 | SHP2 INHIBITORS | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2021-02-10 | — | — | EP | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10017488-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | BOSTON BIOMEDICAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017488-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | BOSTON BIOMEDICAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-0121244-B1 | CEPHALOSPORIN DERIVATIVES | Bristol-Myers Company (US) | 1990-09-12 | — | — | EP | disclosed |
| US-4525473-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1985-06-25 | — | — | US | disclosed |
| EP-0121244-A2 | Cephalosporin derivatives | Bristol-Myers Company (US) | 1984-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | DRD2 797/4885DRD3 718/4885HRH3 1035/4885 |
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | DRD2 439/4885DRD3 364/4885HRH3 1158/4885 |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | DRD2 390/4885DRD3 147/4885HRH3 1194/4885 |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | DRD2 3255/4885DRD3 3530/4885HRH3 512/4885 |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | DRD2 390/4885DRD3 147/4885HRH3 1194/4885 |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | DRD2 390/4885DRD3 147/4885HRH3 1194/4885 |
| US-10017488-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | FGFR3, FGFR1, FGF2 | DRD2 1802/4885DRD3 1532/4885HRH3 1158/4885 |
| US-10934309-B2 | Tricyclic quinone derivative | NQO1, NQO2, SQOR | DRD2 331/4885DRD3 283/4885HRH3 978/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | DRD2 294/4885DRD3 283/4885HRH3 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.